A conserved dendritic-cell regulatory program limits antitumour immunity B Maier, AM Leader, ST Chen, N Tung, C Chang, J LeBerichel, ... Nature 580 (7802), 257-262, 2020 | 584 | 2020 |
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells F Baharom, RA Ramirez-Valdez, KKS Tobin, H Yamane, CA Dutertre, ... Nature immunology 22 (1), 41-52, 2021 | 133 | 2021 |
Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms C Cimen Bozkus, V Roudko, JP Finnigan, J Mascarenhas, R Hoffman, ... Cancer discovery 9 (9), 1192-1207, 2019 | 81 | 2019 |
Mutation-derived neoantigen-specific T-cell responses in multiple myeloma D Perumal, N Imai, A Laganà, J Finnigan, D Melnekoff, VV Leshchenko, ... Clinical Cancer Research 26 (2), 450-464, 2020 | 78 | 2020 |
Computational pipeline for the PGV-001 neoantigen vaccine trial A Rubinsteyn, J Kodysh, I Hodes, S Mondet, BA Aksoy, JP Finnigan, ... Frontiers in immunology 8, 1807, 2018 | 59 | 2018 |
TGFβ Receptor 1: An Immune Susceptibility Gene in HPV-Associated Cancer C Levovitz, D Chen, E Ivansson, U Gyllensten, JP Finnigan, S Alshawish, ... Cancer research 74 (23), 6833-6844, 2014 | 46 | 2014 |
Mutation-derived tumor antigens: novel targets in cancer immunotherapy JP Finnigan Jr, A Rubinsteyn, J Hammerbacher, N Bhardwaj Oncology 29 (12), 970-970, 2015 | 18 | 2015 |
Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer JP Finnigan, AG Sikora Current oncology reports 16, 1-8, 2014 | 14 | 2014 |
Dendritic cell strategies for eliciting mutation-derived tumor antigen responses in patients S Balan, J Finnigan, N Bhardwaj The Cancer Journal 23 (2), 131-137, 2017 | 11 | 2017 |
Immune checkpoint blockade enhances mutated calreticulin-induced t cell immunity in myeloproliferative neoplasms CC Bozkus, JP Finnigan, J Mascarenhas, R Hoffman, N Bhardwaj, ... Blood 130, 384, 2017 | 7* | 2017 |
A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies. A Blazquez, A Rubinsteyn, J Kodysh, JP Finnigan, TU Marron, M Meseck, ... Journal of Clinical Oncology 37 (15_suppl), e14307-e14307, 2019 | 4 | 2019 |
Structural basis for self-discrimination by neoantigen-specific TCRs JP Finnigan, JH Newman, Y Patskovsky, L Patskovska, AS Ishizuka, ... Nature Communications 15 (1), 2140, 2024 | 1 | 2024 |
Abstract LB048: An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001) TU Marron, M Saxena, N Bhardwaj, M Meseck, A Rubinsteyn, J Finnigan, ... Cancer Research 81 (13_Supplement), LB048-LB048, 2021 | 1 | 2021 |
Abstract CT173: PGV-001: A phase I trial of a multipeptide personalized neoantigen vaccine in the adjuvant setting J Kodysh, T Marron, A Rubinsteyn, T O'Donnell, J Finnigan, A Blazquez, ... Cancer Research 80 (16_Supplement), CT173-CT173, 2020 | 1 | 2020 |
Abstract a022: Computational pipeline for a personalized genomic vaccine trial A Rubinsteyn, I Hodes, T O'Donnell, SF Mondet, JP Finnigan, ... Cancer Immunology Research 4 (11_Supplement), A022-A022, 2016 | 1 | 2016 |
Abstract CT270: Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting M Saxena, T Marron, J Kodysh, A Rubinsteyn, J Finnigan, A Blasquez, ... Cancer Research 83 (8_Supplement), CT270-CT270, 2023 | | 2023 |
364 Antigen abundance and TCR avidity impact T cell-mediated tumor recognition in novel B16F10 ACT model J Newman, J Finnigan, A Ishizuka, G Lynn, A Rubinsteyn, T O’Donnell, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting T Marron, J Kodysh, A Rubinsteyn, J Finnigan, A Blazquez, M Saxena, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | | 2020 |
A conserved dendritic-cell regulatory program limits antitumour immunity (vol 580, pg 257, 2020) B Maier, AM Leader, ST Chen, N Tung, C Chang, J LeBerichel, ... Nature 582 (7813), E17-E17, 2020 | | 2020 |
A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers AB Blazquez, A Rubinsteyn, J Kodysh, JP Finnigan, T Marron, RL Sabado, ... CANCER IMMUNOLOGY RESEARCH 7 (2), 2019 | | 2019 |